Clarity Pharmaceuticals Ltd

Climate Impact & Sustainability Data (2022-07 to 2023-06)

Clarity's Targeted Copper Theranostic (TCT) platform offers significant environmental advantages over current-generation radiopharmaceuticals due to the unique characteristics of copper isotopes. Copper-67 production is more environmentally friendly than Lutetium-177, using readily available zinc as a source material instead of rare earth elements, minimizing radioactive waste, and reducing reliance on aging nuclear reactors.

Successfully completed the first three cohorts of the 64Cu/67Cu-SARTATE trial for children with neuroblastoma and are recruiting in the final cohort. Progressed the diagnostic 64Cu-SARTATE product in neuroendocrine tumors (NETs). Promoted 12% of staff members to senior positions in FY22-23. No reported lost time to injuries in FY2022-2023. Supported various charities including The EVAN Foundation, The Kids’ Cancer Project, Neuroblastoma Australia, and Story Factory.

Lodged Corporate Governance Statement with ASX on 29 September 2023, outlining key corporate governance principles and practices aligned with ASX Corporate Governance Council recommendations. Implemented and monitored corporate governance frameworks, policies, and committees, including an Audit and Risk Committee and a Nomination & Remuneration Committee. Implemented cybersecurity awareness training for all team members.

Competitive remuneration and internal promotion opportunities.
Partnering with NorthStar for reliable copper-67 supply and establishing a Center of Excellence with Idaho State University.

Frameworks Used: SASB's Biotechnology & Pharmaceuticals Sustainability Accounting Standard